Zacks: Brokerages Set $15.50 Price Target for Leap Therapeutics, Inc. (LPTX)
Shares of Leap Therapeutics, Inc. (NASDAQ:LPTX) have earned an average broker rating score of 1.50 (Buy) from the two analysts that provide coverage for the company, Zacks Investment Research reports. One investment analyst has rated the stock with a buy recommendation and one has assigned a strong buy recommendation to the company.
Brokers have set a twelve-month consensus price objective of $15.50 for the company and are forecasting that the company will post ($0.52) earnings per share for the current quarter, according to Zacks. Zacks has also given Leap Therapeutics an industry rank of 113 out of 265 based on the ratings given to related companies.
Separately, Zacks Investment Research raised shares of Leap Therapeutics from a “sell” rating to a “hold” rating in a research report on Tuesday, May 30th.
Shares of Leap Therapeutics (NASDAQ LPTX) traded down 5.0202% during mid-day trading on Friday, hitting $6.0977. The company had a trading volume of 14,457 shares. Leap Therapeutics has a 52-week low of $5.40 and a 52-week high of $10.10. The firm’s market capitalization is $57.29 million. The firm has a 50-day moving average price of $6.75 and a 200 day moving average price of $7.27.
Leap Therapeutics (NASDAQ:LPTX) last issued its quarterly earnings results on Friday, August 11th. The company reported ($0.74) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.71) by $0.03. Analysts expect that Leap Therapeutics will post ($3.36) earnings per share for the current year.
An institutional investor recently bought a new position in Leap Therapeutics stock. Renaissance Technologies LLC acquired a new stake in Leap Therapeutics, Inc. (NASDAQ:LPTX) during the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund acquired 45,445 shares of the company’s stock, valued at approximately $417,000. Renaissance Technologies LLC owned approximately 0.48% of Leap Therapeutics as of its most recent SEC filing. Institutional investors and hedge funds own 0.88% of the company’s stock.
Leap Therapeutics Company Profile
Leap Therapeutics, Inc, formerly HealthCare Pharmaceuticals, Inc, is a clinical-stage biopharmaceutical company. The Company engages in acquiring and developing therapeutics in cancer biology. Its lead product candidates for use in clinical trials include TRX518 and DKN-01. DKN-01 is a monoclonal antibody targeting Dickkopf-related protein 1 (DKK1).
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Leap Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Leap Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.